Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382023395> ?p ?o ?g. }
- W4382023395 abstract "Background Despite numerous immunotherapy and chemotherapy regimens available for patients with extensive-stage small cell lung cancer (ES-SCLC), it remains unclear which regimen is the most effective and safest; relative studies comparing such regimens are scarce. Objective The aim of this study was to investigate the efficacy and safety of first-line immunotherapy combinations with chemotherapy for patients with extensive-stage small cell lung cancer. In addition, for the first time, comparisons among the first-line systemic regimens on OS and PFS in ES-SCLC by each time node were made. Methods Databases including PubMed, Embase, Cochrane Library, Scopus, Google Scholars, and ClinicalTrials.gov, and major international conferences were searched for randomized controlled trials (RCTs) regarding comparing immunotherapy combinations with chemotherapy as first-line treatments for patients with advanced ES-SCLC from inception to 1 November. Hazard ratios (HRs) and odds ratios (ORs) were generated for dichotomous variants by RStudio 4.2.1. The outcomes comprised overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse events of grade 3 or higher (Grade ≥ 3 AEs). Results Eventually, a total of nine RCTs reporting 4,352 individuals with nine regimens were enrolled. The regimens were ipilimumabnu (Ipi), atezolizumab (Atez), durvalumab plus tremelimumab (Durv-Trem), durvalumab (Durv), pembrolizumab (Pemb), adebrelimab (Adeb), serplulimab (Serp), atezolizumab plus tiragolumab (Atez-Tira), and nivolumab (Nivo). With regard to OS, serplulimab (HR = 0.63, 95% CI: 0.49 to 0.81) was found to yield the best OS benefit when compared with chemotherapy. Meanwhile, serplulimab had the highest probability (46.11%) for better OS. Furthermore, compared with chemotherapy, serplulimab significantly increased the OS rate from the 6th to the 21st month. With regard to PFS, serplulimab (HR = 0.47, 95% CI: 0.38 to 0.59) was found to yield the best PFS benefit when compared with chemotherapy. Simultaneously, serplulimab had the highest probability (94.48%) for better PFS. Serplulimab was also a long-lasting first-line regimen in both OS and PFS from a longitudinal perspective. In addition, there was no significant difference among the various treatment options for ORR and grade ≥3 AEs. Conclusion Considering OS, PFS, ORR, and safety profiles, serplulimab with chemotherapy should be recommended as the best therapy for patients with ES-SCLC. Certainly, more head-to-head studies are needed to confirm these findings. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42022373291." @default.
- W4382023395 created "2023-06-27" @default.
- W4382023395 creator A5008171524 @default.
- W4382023395 creator A5014556358 @default.
- W4382023395 creator A5025687268 @default.
- W4382023395 creator A5033020983 @default.
- W4382023395 creator A5050445168 @default.
- W4382023395 creator A5080121245 @default.
- W4382023395 date "2023-06-26" @default.
- W4382023395 modified "2023-09-26" @default.
- W4382023395 title "Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis" @default.
- W4382023395 cites W1617328014 @default.
- W4382023395 cites W1919288105 @default.
- W4382023395 cites W2068834940 @default.
- W4382023395 cites W2074552727 @default.
- W4382023395 cites W2101156795 @default.
- W4382023395 cites W2155599713 @default.
- W4382023395 cites W2168234885 @default.
- W4382023395 cites W2170260373 @default.
- W4382023395 cites W2251438188 @default.
- W4382023395 cites W2480201404 @default.
- W4382023395 cites W2529904548 @default.
- W4382023395 cites W2537295025 @default.
- W4382023395 cites W2888569999 @default.
- W4382023395 cites W2893960509 @default.
- W4382023395 cites W2903653714 @default.
- W4382023395 cites W2909486828 @default.
- W4382023395 cites W2909918855 @default.
- W4382023395 cites W2913381773 @default.
- W4382023395 cites W2964993184 @default.
- W4382023395 cites W2977392388 @default.
- W4382023395 cites W2979920955 @default.
- W4382023395 cites W2994949240 @default.
- W4382023395 cites W2995440672 @default.
- W4382023395 cites W3028669282 @default.
- W4382023395 cites W3029678115 @default.
- W4382023395 cites W3030178583 @default.
- W4382023395 cites W3038922416 @default.
- W4382023395 cites W3091379564 @default.
- W4382023395 cites W3091681691 @default.
- W4382023395 cites W3106581657 @default.
- W4382023395 cites W3110002524 @default.
- W4382023395 cites W3118711697 @default.
- W4382023395 cites W3121328438 @default.
- W4382023395 cites W3132603187 @default.
- W4382023395 cites W3134820202 @default.
- W4382023395 cites W3152535944 @default.
- W4382023395 cites W3169047117 @default.
- W4382023395 cites W3203615375 @default.
- W4382023395 cites W3206940911 @default.
- W4382023395 cites W4200477716 @default.
- W4382023395 cites W4200478239 @default.
- W4382023395 cites W4220970211 @default.
- W4382023395 cites W4226266653 @default.
- W4382023395 cites W4237055762 @default.
- W4382023395 cites W4280546819 @default.
- W4382023395 cites W4281787927 @default.
- W4382023395 cites W4282008853 @default.
- W4382023395 cites W4284884589 @default.
- W4382023395 cites W4288887302 @default.
- W4382023395 cites W4294754570 @default.
- W4382023395 cites W4297251744 @default.
- W4382023395 cites W4304690543 @default.
- W4382023395 cites W4313576839 @default.
- W4382023395 doi "https://doi.org/10.3389/fimmu.2023.1197044" @default.
- W4382023395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37435087" @default.
- W4382023395 hasPublicationYear "2023" @default.
- W4382023395 type Work @default.
- W4382023395 citedByCount "0" @default.
- W4382023395 crossrefType "journal-article" @default.
- W4382023395 hasAuthorship W4382023395A5008171524 @default.
- W4382023395 hasAuthorship W4382023395A5014556358 @default.
- W4382023395 hasAuthorship W4382023395A5025687268 @default.
- W4382023395 hasAuthorship W4382023395A5033020983 @default.
- W4382023395 hasAuthorship W4382023395A5050445168 @default.
- W4382023395 hasAuthorship W4382023395A5080121245 @default.
- W4382023395 hasBestOaLocation W43820233951 @default.
- W4382023395 hasConcept C121608353 @default.
- W4382023395 hasConcept C126322002 @default.
- W4382023395 hasConcept C143998085 @default.
- W4382023395 hasConcept C207103383 @default.
- W4382023395 hasConcept C2775949291 @default.
- W4382023395 hasConcept C2776256026 @default.
- W4382023395 hasConcept C2777701055 @default.
- W4382023395 hasConcept C2777742743 @default.
- W4382023395 hasConcept C2780030458 @default.
- W4382023395 hasConcept C2780057760 @default.
- W4382023395 hasConcept C2781413609 @default.
- W4382023395 hasConcept C44249647 @default.
- W4382023395 hasConcept C71924100 @default.
- W4382023395 hasConceptScore W4382023395C121608353 @default.
- W4382023395 hasConceptScore W4382023395C126322002 @default.
- W4382023395 hasConceptScore W4382023395C143998085 @default.
- W4382023395 hasConceptScore W4382023395C207103383 @default.
- W4382023395 hasConceptScore W4382023395C2775949291 @default.
- W4382023395 hasConceptScore W4382023395C2776256026 @default.
- W4382023395 hasConceptScore W4382023395C2777701055 @default.
- W4382023395 hasConceptScore W4382023395C2777742743 @default.
- W4382023395 hasConceptScore W4382023395C2780030458 @default.
- W4382023395 hasConceptScore W4382023395C2780057760 @default.